stockportfolio.pro
Shattuck Labs, Inc. (STTK)
Healthcare · Biotechnology · NasdaqGS
Shattuck Labs, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $9.89M | $9.93M | $30.02M | $652,000 | $1.66M | $5.72M | $1.00M |
| Gross profit | — | — | — | — | — | — | — |
| Net income | $-23.98M | $-36.60M | $-44.97M | $-101.94M | $-87.30M | $-75.41M | $-48.81M |
| Net margin | -242.6% | -368.5% | -149.8% | -15635.7% | -5268.4% | -1318.1% | -4880.9% |
Source: Shattuck Labs, Inc. SEC filings (10-K).
Explore 7 years of Shattuck Labs, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track STTK in your portfolio →
Shattuck Labs, Inc. financial history by metric
About Shattuck Labs, Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs, Inc. — frequently asked questions
What is Shattuck Labs, Inc.'s revenue?
Shattuck Labs, Inc. (STTK) reported revenue of $1.00M for fiscal year 2025, down 82.5% from the prior year, according to its SEC filings.
Is Shattuck Labs, Inc. profitable?
No — STTK reported a net loss of $-48.81M in fiscal 2025.
What is STTK's P/E ratio?
Shattuck Labs, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Shattuck Labs, Inc. growing?
STTK's revenue grew at roughly -36.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Shattuck Labs, Inc. have?
As of fiscal year 2025, STTK carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Shattuck Labs, Inc.'s market cap?
Shattuck Labs, Inc. (STTK) has a market capitalization of about $319.76M, based on the latest data in our nightly-refreshed cache.
When does Shattuck Labs, Inc.'s fiscal year end?
STTK's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Shattuck Labs, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.